The use of neoantigens in therapy has demonstrated the ability to elicit a strong T cell mediated immune response. Several therapy candidates are being investigated both as monotherapies and in combination with various immune checkpoint inhibitors, such as atezolizumab, durvalumab, ipilimumab, and nivolumab. Of these, certain pipeline candidates have already entered mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years.
To order this 320+ page report, which features 110+ figures and 140+ tables, please visit this link
The USD 3 billion (by 2030) financial opportunity within the neoantigens market has been analyzed across the following segments:
Type of target disease indication
Bone cancer
Colorectal cancer
Gynecological cancer
Non-small cell lung cancer
Renal cell carcinoma
Other cancers
Type of neoantigens
Personalized neoantigens
Off-the-shelf neoantigens
Type of immunotherapy
Dendritic cell vaccines
DNA / RNA-based vaccines
Protein / peptide-based vaccines
TIL-based therapies
Route of administration
Intradermal
Intravenous
Subcutaneous
Other routes
Key geographical regions
North America
Europe
Rest of the World
The report features inputs from eminent industry stakeholders, according to whom neoantigen targeted therapies are expected to be the next big step in cancer immunotherapy. Similar to CAR-T cell therapies, these therapies have, so far, demonstrated significant therapeutic potential and promising clinical outcomes. The report includes detailed transcripts of discussions held with the following experts:
Gabriel Nistor (Chief Science Officer, AIVITA Biomedical)
Ella Sorani (Vice President Research and Development, BioLineRx)
Heinz Lubenau (Chief Operating Officer & Co-founder, VAXIMM)
The Neoantigen Targeted Therapies, 2019-2030 report features the following companies, which we identified to be key players in this domain:
Bavarian Nordic
Genocea Biosciences
Press Release: Variation 3 (Format 4)
Gradalis
Immunicum
Immunovative Therapies
Iovance Biotherapeutics
Medigene
Neon Therapeutics
Precision Biologics
Vaxon Biotech
Table of Contents
1. Preface
2. Executive Summary
3. Introduction
4. Market Overview
5. Company Profiles: Neoantigen Targeted Therapies
6. Publication Analysis
7. Patent Analysis
8. Partnerships and Collaborations
9. Funding and Investment Analysis
10. Market Forecast and Opportunity Analysis
11. Concluding Remarks
12. Executive Insights
13. Appendix 1: Tabulated Data
14. Appendix 2: List of Companies and Organizations
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/neoantigen-targeted-therapies-market-2019-2030/257.html
Contact Details:
Gaurav Chaudhary
+1 (415) 800 3415
[email protected]